SLC2A1 and Miyoshi myopathy: By using an orthogonal-targeting GLUT1 and VLA-4 strategy to, respectively, deliver the 18FDG and NM-TC to the MM cells, we aimed to minimize the potential saturation or depletion of the targeted receptors.